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Background: Psoriasin (S100A7) is a member of the S100 gene family. Alteration of Psoriasin expression has
previously been reported to play an important role in cancer aggressive behaviour. The current study sought to
investigate the level of Psoriasin expression at the mRNA level in a cohort of patients with non-small cell lung
cancer (NSCLC), the association with clinical implication and outcomes, and the molecular and cellular impact of
the protein on lung cancer cells.
Methods: Fresh frozen NSCLC cell carcinoma tissues, along with matched normal tissues were obtained from 83
NSCLC patients who received curative resection from January 2003 to December 2011. The expression of Psoriasin
in the NSCLC specimens was assessed using both quantitative real time PCR (QPCR) and immunochemical staining.
Knockdown and forced expression of Psoriasin in NSCLC cell lines were carried out using constructed plasmid
vectors carrying either ribozyme transgenes targeting human Psoriasin or full-length coding sequence, respectively.
The effect of Psoriasin on the functions of NSCLC cells was determined using a variety of in vitro cell function
assays.
Results: Higher mRNA levels of Psoriasin were observed in tumour tissues when compared to both the paired
normal background tissues and none paired normal tissues (p = 0.0251 and 0.0195). The mRNA level of Psoriasin
was found to be higher in the squamous carcinoma (P=0.035). Higher Psoriasin expression is associated with poor
prognosis. The cell function tests had supportive results to the clinical findings. Over-expression of Posriasin in lung
cancer cells (SK-MES-1) resulted in an increase in in vitro growth and invasiveness. In contrast, Psoriasin knockdown
suppressed cell growth and invasion (P<0.05), but increased cell adhesion (P<0.05).
Conclusions: Psoriasin expression is increased in lung cancer, more specifically in lung squamous carcinoma
compared with adenocarcinoma, and is associated with poor prognosis. Psoriasin plays crucial roles in regulating
the growth and invasion of lung cancer cells.
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Non-small cell lung cancer (NSCLC) is highly aggressive.
Better prognosis and clinical outcomes mainly rely on
early detection and curative resection. However, some of
these early stage patients have poor prognosis due to me-
tastasis. Real-time-quantitative-PCR-based assay of certain* Correspondence: yel@cf.ac.uk
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reproduction in any medium, provided the orgenes may help to identify patients of early-stage NSCLC
with higher risks of poorer prognosis [1]. Psoriasin, also
known as S100A7, is a member of the S100 gene family
that was identified as a 11.4 kDa protein induced in the
epidermis isolated from psoriasis [2]. The Psoriasin gene
maps to chromosome 1q21.2-q22, within a region that
encompasses at least 12 of the S100 gene family and sev-
eral other epidermal differentiation genes [3]. Other mem-
bers of the S100 calcium binding proteins have been
implicated in a range of biological processes, including
tumour metastasis [4]. Alteration of Psoriasin (S100A7)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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portant role in cancer aggressive behaviour [5]. Psoriasin
is likely to be one of those molecules associated with the
development of the invasive phenotype and the transition
from preinvasive to invasive in breast cancer with the cap-
ability for subsequent metastasis associated with poor out-
come in oestrogen receptor-negative invasive breast
cancer [6]. While Kesting et al. reported that Psoriasin is a
positive marker for oral carcinogenesis and early tumour
progression [7]; recent studies have however shown that
down-regulation of Psoriasin in ER negative breast cancer
cells inhibits EGF-induced migration [8]. Psoriasin has
also been shown to enhance tumour growth in ER nega-
tive cells by regulating prosurvival mechanisms, such asTable 1 Psoriasin expression and clinical/pathological charact
Clinical/pathological features Sample no.
Tumour tissue 83
Background tissue 69
Paired tumour tissue 61

























Former or current smoker 49
Non smoker 23NF-κB and AKT pathways [9]. Morgan et al. identified a
novel interaction between Psoriasin and β6-integrin and
demonstrated that it was required for αVβ6-integrin
dependent invasion by cancer cells. Inhibition of this
interaction may represent a novel therapeutic strategy to
target carcinoma invasion [10]. Evidence of Psoriasin hav-
ing a role in lung cancer is sparse. It has been recently
shown that Psoriasin expression was associated with brain
metastases of lung squamous carcinoma and may be a po-
tential biomarker [11]. However, function of Psoriasin in
NSCLC remains unknown.
The current study sought to investigate the level of ex-
pression of Psoriasin at the mRNA level in a group of
surgical patients with NSCLC and to examine theeristics of lung cancer
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outcomes. We also provide new insights into the bio-
logical functions of Psoriasin in NSCLC cell lines.Methods
Cell lines and human lung cancer specimens
Human lung squamous carcinoma SK-MES-1 and
human lung adenocarcinoma A549 cells were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). Cells were routinely cultured with
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% foetal calf serum, penicillin and
streptomycin (Gibco BRC, Paisley, Scotland, UK). Fresh
frozen NSCLC cell carcinoma tissues at TNM stages
of I to IIIa, along with matched normal tissues, were
obtained from 83 patients who received curative resec-
tion in Peking University Cancer Hospital and Xuanwu
Hospital of Capital Medical University from January
2003 to December 2011. Ethical approval was provided
by both Peking University Cancer Hospital and Xuanwu
Hospital of Capital Medical University Ethics Commit-
tees. Clinical information of the patients is given in
Table 1. These tissues were collected immediately after
surgical resection and stored in the Tissue Bank of
Peking University Oncology School and Xuanwu Hos-
pital Lung Cancer Laboratory. Clinic-pathological fac-
tors, including age, sex, histological types of tumours,
TNM stage, and lymph node metastasis were recorded
and stored in the patients’ database. Patients were fol-
lowed up from the day of operation to December 2011.
The follow-up intervals were calculated as survival inter-
vals after surgery.RNA isolation and reverse transcription polymerase chain
reaction
Total RNA was isolated from the homogenized NSCLC
tissues (83 pairs of specimens) and cell lines using Total
RNA Isolation Reagent (ABgene™). Reverse transcription
was performed using the Reverse Transcription kit
(Primer design), followed by PCR using a REDTaq™
ReadyMix PCR reaction mix (Sigma-Aldrich, Inc.). The
quality of DNA was verified using GAPDH primers
(sense: 5’-ATGATATCGCCGCGCTCGTC-3’; antisense:
5’-CGCTCGGTGAGGATCTTCA-3’). Psoriasin mRNA
levels were assessed using Psoriasin primers as follow: F:
5-GGGCACAAATTACCTCGCGA, R: 5-CACTGGCTG
CCCCCGGAAC. PCR was performed in a GeneAmp
PCR system 2400 thermocycler (Perkin-Elmer, Norwalk
CT, USA). Cycling conditions for the 16-μl-reaction
mixture were 30s at 94°C for denaturation, 30s at 55°C
for annealing and 30s at 72°C for elongation (30 cycles).
This was followed by a final 10 min extension period at
72°C. PCR products were then separated on a 2%agarose gel. The product was then visualized under
ultraviolet light following ethidium bromide staining.Quantitative real time PCR (QPCR)
QPCR was performed on the Icycler IQ5 system
(Bio-Rad, Hammel Hemstead, UK) to quantify the level
of Psoriasin transcripts in the NSCLC specimens (shown
as copies/μl from internal standard). NSCLC cDNA
samples were then examined for Psoriasin transcript ex-
pression, along with a set of standards and negative con-
trols. The QPCR technique utilised the Amplifluor
system™ (Intergen Inc., England) and QPCR master mix
(BioRad). Pairs of primers were designed using Beacon
Design software (PREMIER Biosoft, Palo Alto, CA):
Psoriasin QPCR primers: ZF: 5-TGTGACAAAAAGGG
CACAAA, ZR: 5-ACTGAACCTGACCGTACACCCAG
CAAGGACAGAAACTC. The underlined sequence in
the reverse primers was the additional Z sequence,
which is complementary to the universal Z probe (TCS
Biologicals Ltd., Oxford, UK). Real-time QPCR condi-
tions were 95°C for 15 min, followed by 60 cycles of
95°C for 20 s, 55°C for 30 s and 72°C for 20 s. QPCR for
GAPDH was also performed on the same samples to
normalize for any residual differences in the initial level
of RNA in the specimens, using a GAPDH quantitation kit
from Perkin-Elmers (Perkin-Elmer, Surrey, England, UK).Immunohistochemical staining of psoriasin
Paraffin sections of NSCLC (n = 16) and paired normal
lung tissues (n = 16) were cut at a thickness of 6 μm.
The sections were first dewaxed using a series of xylene
and rehydrated through descending grades of ethanol
washes. Endogenous peroxidase activity was blocked
with 0.3% hydrogen peroxide for 15 min. For antigen re-
trieval, sections were boiled in 10 mM citrate buffer (pH
6.0) for 10 min. The sections were then immersed in
TBS wash buffer for 10 min to rehydrate and incubated
for 20 min in a horse serum blocking solution before
probing with the Psoriasin antibody (1:100) (ab13680,
Abcam, Cambridge, UK) together with a negative con-
trol without primary antibody. Following extensive
washing, sections were incubated for 30 min with the
secondary biotinylated antibody (Vector Laboratories).
Avidin-biotin complex (Vector Laboratories) was then
applied to the sections for 30 min followed by extensive
washing. Diamino benzidine chromogen (Vector Labora-
tories) was then added to the sections and incubated in
the dark for 10 min. Sections were then counterstained
in Mayer’s haematoxylin and dehydrated in ascending
grades of ethanol before clearing in xylene and mount-
ing under a cover slip. Staining was independently
assessed by the authors.
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transgenes, and transfection
The full sequence of Psoriasin was amplified using the
standard PCR procedure described above and a master mix
with proof reading enzyme, as previously reported [12,13].
The following primers were used for amplification of the full
length human Psoriasin: sense primers, 5’- ATGAGCAA
CACTCAAGCTG; antisense: 5’- ACTGGCTGCCCCCG
GAACA. Correctly amplified product was then cloned into
pEF6/V5-His-TOPO vector (Invitrogen, Paisley, UK).
Multiple clones of E. coli were screened and plasmids from
the clones were sequenced. Purified plasmids were then
electroporated into the SK-MES-1 cell line. Blasticidin
(5 μg/ml final concentration) was used to select stably trans-
fected strains. The control group of cells containing the
same plasmid vector (minus the Psoriasin sequence) was
termed SK-MES-1 PEF. Anti-Psoriasin ribozyme transgenes
were employed to knockdown the expression of Psoriasin in
the A549 cell line, and were generated using the methods
previously described [12]. Briefly, the anti-Psoriasin ham-
merhead ribozyme was designed based on the secondary
structure generated using Zuker’s RNA mFold program.
Then the ribozymes that specifically target Psoriasin
were generated using touchdown PCR with the appropri-
ate primers (sense, 5’-CTGCAGTCACAGGCACTAAG
GAAGTTGGGCTGATGAGTCCGTGAGGA; antisense,
5’-ACTAGTGGCTGGTGTTTGACATTTCGTCCTCAC
GGACT). The constructed ribozyme trangenes were
transfected into A549 cells by way of electroporation.
A549 cells transfected with anti-Psoriasin ribozyme and
the control cells transfected with the empty plasmid vec-
tors were designated as A549 PsoRib and A549 PEF
respectively.
Western blotting
To detect the expression level of FAK in the NSCLC cell
lines, confluent cells were pelleted and then lysed using
a lysis buffer containing 2.4 mg/ml Tris, 4.4 mg/ml
NaCl, 5 mg/ml sodium deoxycholate, 20μg/ml sodium
azide, 1.5% Triton, 100 μg/ml PMSF, 1 μg/ml leupeptin,
and 1 μg/ml aprotinin, for 45 min at 4°C. After lysis and
centrifugation at 13,000 rpm for 15min, protein concen-
tration of each sample was measured using an improved
Lowary assay (DC Protein Assay kit, Bio-Rad). The sam-
ples were adjusted to equal concentrations with sample
buffer and then boiled at 100°C for 5 min, before separ-
ation on a 10% polyacrylamide gel. Following electro-
phoresis, these separated proteins were blotted onto
nitrocellulose membrane and blocked in 10% skimmed
milk (w/v in TBS) for 1 hour. The membranes were then
probed with the anti-phosphorylated FAK at Tyrosine
residue 407 (Santa Cruz, CA, USA) and anti-GAPDH-
antibody (Santa-Cruz Biotechnologies, California, USA)
as internal control, followed by a peroxidase-conjugatedsecondary antibody (1:1,000). Protein bands were visua-
lised using an ECL system (Amersham, UK), and photo-
graphed using an UVITech imager (UVITech, Inc.).
In vitro cell growth assay
Cells were plated into 96-well plates at density of 2,000
cells/well. The cells were then fixed in 4% formaldehyde
after 1, 3 and 5 days respectively. 0.5% crystal violet (w/v)
was used to stain cells. Following washing, the stained
crystal violet was dissolved with 10% (v/v) acetic acid and
the absorbance was determined at a wavelength of 540
nm using a spectrophotometer (Bio-Tek, ELx800). The
absorbance of each cell line at day3 and day5 were then
normalised against day1 absorbance.
Cell matrix adhesion assay
The cell matrix adhesion assay was done as previously
described [14]. A 96-well plate was precoated with 5 μg
of Matrigel and allowed to dry. Following rehydration by
serum free medium, 20,000 cells were added to each
well, and treated with or without 200nM FAK inhibitor
(FP573228, Tocris, Bristol, UK). After 45 min of incuba-
tion non-adherent cells were washed off using BSS buf-
fer. The remaining cells were fixed with 4% formalin and
stained with 0.5% crystal violet. Following washing, the
stained crystal violet was dissolved with 10% (v/v) acetic
acid and the absorbance was determined at a wavelength
of 540 nm using a spectrophotometer (Bio-Tek,
ELx800).
Wounding/migration assay
The wounding assay was performed as previously
described [15]. The cells were seeded at a density of
25,000 per well into a 24-well plate and allowed to reach
confluence. The monolayer of cells was then scraped
with a fine gauge needle to create a wound. The move-
ment of cells to close the wound was recorded as
described previously using a time-lapsed video system.
Images were captured from the videotape at the equiva-
lent of 15 min intervals in real-time and stored as a
series of gray scale bitmap images. The movement of
single cells within a colony was analyzed by tracking
each cells boundary, for each frame in a series, using the
Optimas 6.0 motion analysis (Meyer Instruments,
Houston, Texas).
In vitro invasion assay
Transwell inserts (upper chamber) with 8 μm pore size
were coated with 50 μg of Matrigel (Collaborative Re-
search Products, Bedford, Massachusetts, USA) and air-
dried. Following rehydration, cells were seeded at a
density of 20,000 per insert and allowed to invade for 3
days. After incubation, cells that had migrated through
the matrix and adhered to the other side of the inserts
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ume) crystal violet, and counted under a microscope.
Statistical analysis
Statistical analysis was performed using MINITAB ver-
sion 13.32 (Minitab Inc., State College, PA). The rela-
tionship between Psoriasin expression and tumour
grade, TNM staging and nodal status was assessed by
Mann–Whitney U test. The error bars shown in the
graphs represent the STDEV. Survival was analyzed
using Kaplan-Meier survival analysis. Differences were
considered statistically significant at p < 0.05.Figure 1 Increased expression of Psoriasin in human lung cancer. A, E
background tissues (A5-A7). Staining of Psoriasin in tumour cells is indicate
carcinoma specimen and background tissue. A9 is the negative control of
overall survival of lung cancer.Results
The expression of Psoriasin mRNA and protein in NSCLC
tissues
Psoriasin transcript expression was examined in the lung
specimens of 83 NSCLC patients using real-time quanti-
tative PCR (Table 1) (expressed as mean Psoriasin tran-
script copies/μl of RNA from 50 ng total RNA and
standardized with GAPDH). Higher mRNA expression
levels of Psoriasin were observed in tumour tissues
p=0.0251 and p=0.0195 when compared to the paired
normal background tissues and unpaired normal tissues,
respectively.xpression of Psoriasin in squamous carcinoma (A1 to A3) and paired
d by arrows. A4 and A8 are matched HE staining for the squamous
IHC using the secondary antibody alone. B, Psoriasin expression and
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protein level, we performed immunohistochemical ana-
lysis of Psoriasin in the paired human NSCLC and nor-
mal tissue sections, using a specific anti-Psoriasin
monoclonal antibody (n = 16). Psoriasin was almost ab-
sent from normal tissues and adenocarcinoma tumours.
However, it was interesting to note that squamous car-
cinoma tissues had a highly positive staining of Psoria-
sin, mostly in the cytoplasmic region of the tumour cells
(Figure 1).
The association of Psoriasin expression with clinical and
histopathological features of NSCLC
The relation of Psoriasin expression to specific patho-
logical status was assessed in the present study. In com-
parison with its expression in adenocarcinoma tissues,
higher levels of Psoriasin transcripts were seen in the
squamous carcinoma tissues (p = 0.035). The patients
who were former or current smokers had a higher Psor-
iasin expression compared with the patients who did not
smoke at all (p=0.0372).Figure 2 Knockdown and forcing expression of Psoriasin in NSCLC ce
design anti-Psoriasin ribozymes. B, Establishment of SK-MES-1 cells for expr
using RT-PCR.The relationships between Psoriasin expression and
clinical TNM staging and Lymph node status were also
analyzed. Statistical analysis showed no significant differ-
ence among different groups (Table 1). An average of
Psoriasin transcript levels in the tumours of TNM stage
2 was used as a threshold between the high and low ex-
pression. Kaplan-Meier analysis showed poorer overall
survival in the patients with higher expression levels of
Psoriasin, p=0.017 compared with the patients that had
lower expression of Psoriasin (Figure 1B). The average
survival of lower Psoriasin expression patients was 34.4
months (95%CI, 30.9-37.8 months), while that of patient
with higher expression was 27.7 months (95%CI, 20.6-
34.8 months).
Creation of sublines of lung cancer cells with psoriasin
over-expression and knockdown
A panel of NSCLC cancer cell lines was examined for
the presence of Psoriasin using RT-PCR. Psoriasin tran-
script was detectable in A549 cell lines, but not
expressed in the SK-MES-1 cell lines (Figure 2). Tolls. A, Secondary structure of Psoriason mRNA which was used to
essing Psoriasin and A549 cells for Psoriasin knockdown were verified
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SK-MES-1 for Psoriasin over-expression, and A549 cells
for knockdown of Psoriasin using an anti-Psoriasin
transgene (based on the secondary structure of Psoriasin
mRNA, Figure 2A). Psoriasin over-expression was suc-
cessfully established in SK-MES-1 cells (SK-MES-1
PsoExp) after transfection compared with that in SK-
MES-1 WT (SK-MES-1-wild-type) and empty vector
control (SK-MES-1 PEF) cells (Figure 2B). Psoriasin pre-
senting in the wild type (A549 WT) and empty vector
control cells (A549 PEF) cells was reduced in the A549
Psoriasin knockdown cells (A549 PsoRib). These Psoria-
sin modified sublines were used for the following
in vitro studies.
Effects of Psoriasin over-expression and
knockdown on in vitro growth of NSCLC cells
We first determined the effect of Psoriasin over-
expression on in vitro cell growth. An increase was seenFigure 3 Influences on in vitro growth and adhesion of NSCLC cells b
1 PsoExp cells was increased compared to SK-MES-1 PEF control at day3 an
exhibited reduced growth over 3 days and 5 days culture, P<0.001 and P=
SK-MES-1 PsoExp cells was decreased (p=0.003). D, A549 PsoRib cells had ain the growth of SK-MES-1 cells of Psoriasin overexpres-
sion. SK-MES-1 PsoExp NSCLC cells had a significantly
increased rate of growth, p=0.001 compared to the con-
trols (Figure 3A). This was consistent with observations
in A549 PsoRib cells, in which Psoriasin expression had
been knocked down and a decreased growth was seen,
p < 0.001 compared to the control groups (Figure 3B).
Impact on in vitro cell matrix adhesion by Psoriasin over-
expression or knockdown
We further examined the influence of Psoriasin on the
adhesive nature of these NSCLC cells. Over-expressing
Psoriasin in SK-MES-1 significantly reduced the adhe-
sive properties compared to the control groups
(Figure 3C). In contrast, knockdown of Psoriasin expres-
sion resulted in a remarkable increase in adhesive ability
of A549 cells (Figure 3D). To investigate the pathway by
which the adhesion function may be altered, we evalu-
ated the activation of the focal adhesion kinase, FAK.y Psoriasin over-expression and knockdown. A, Growth of SK-MES-
d day5 (P=0.001 and P=0.001 respectively). B, A549 PsoRib cells
0.001 compared to A549 PEF control, respectively. C, Cell adhesion in
remarkable increase in cell adhesion (P<0.001).
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PsoRib compared to A549 PEF control (Figure 4A). Fur-
thermore, the increased adhesion by Psoriasin knock-
down was diminished by the addition of FAK inhibitor
(Figure 4B).
Effects of Psoriasin manipulation on in vitro invasion
Over-expression of Psoriasin in SK-MES-1 resulted in a
marked elevation of invasion (Figure 5A). This was also
confirmed by further determination of the invasive na-
ture of Psoriasin knockdown cells. A549 PsoRib cells
were significantly less invasive than the control cells
which expressed Psoriasin (Figure 5B).
Effects of Psoriasin over-expression or knockdown on
in vitro migration
In vitro wounding assay was employed to examine the
influence of Psoriasin over-expression or knockdown onFigure 4 Involvement of Focal Adhesion Kinase (FAK) in
adhesion of NSCLC cells affected by Psoriasin. A, An increased
phosphorylation of FAK was seen in A549 cells after knockdown of
Psoriasin, while no obvious effect was seen in the SK PsoExp cells.
B, Addition of 200nM FAK inhibitor diminished the effect of Psoriasin
knockdown on adhesion of A549 cells. * indicates p<0.01 v.s.
controls.the migration of NSCLC cells. Over-expression of
Psoriasin did not influence the migratory nature of SK-
MES-1 cells (Figure 5C). The result was also consistent
with observations in the Psoriasin knockdown cells,
A549 PsoRib cells, where the motility was similar to that
of the control cells (Figure 5D).
Discussion
Psoriasin has been considered to be expressed in a cell
type or tissue specific manner. S100A7 is over-expressed
in hyperproliferative skin disease-psoriasis [2] and is also
associated with the early stages or invasion of certain can-
cers [6,16]. Classifying a NSCLC to be an adenocarcin-
oma, squamous cell carcinoma or large cell carcinoma is
generally difficult, especially for cancers with poorly differ-
entiated morphologies [17-20]. Meanwhile, it has become
apparent that adenocarcinoma and squamous carcinoma
of the lungs have distinct mutation profiles, which under-
line their divergent responses to targeted therapies [21].
Therefore, identification and characterisation of biomar-
kers are of great value in diagnosis and therapy for specific
pathological types of lung cancer. In the current study, we
have shown that Psoriasin is frequently down-regulated or
absent from lung adnocarcinoma cancer cells and normal
lung tissues, but is often over-expressed in lung squamous
carcinoma tissues. It has been reported that elevated Psor-
iasin protein can be detected in the sera of patients with
lung squamous cell carcinomas rather than adenocarcin-
oma [22]. These findings may make Psoriasin an indicator
for differential diagnosis for lung squamous carcinoma
and adenocarcinoma. We also report that the levels of
Psoriasin are correlated with the clinical outcomes and
long term survival of the patients with NSCLC.
The study further demonstrates that over-expression
of Psoriasin is linked to the elevation of growth, invasion
and motility of NSCLC cells in vitro. The knockdown of
Psoriasin inhibits the growth and invasion of NSCLC
cells, which is also supported by findings in other malig-
nancies [12,23]. The over-expression of Psoriasin on the
other hand resulted in decreased cell adhesion while
knockdown increased it. The influence of Psoriasin on
cell adhesion was impaired by FAK inhibitor. Psoriasin
has been shown to be up-regulated in the cells losing at-
tachment [24]. This appears to be not just a response of
cells when they lose attachment but, the expression of
Psoriasin in the cells can also affect the adhesion of the
cells which we have seen in our studies of Psoriasin in
cell lines of different cancers. For example, in the
current study, A549 cells exhibited an enhanced adhe-
sion after the knockdown of Psoriasin which was accom-
panied with an increased p-FAK. It suggests that
Psoriasin is inversely associated with cell adhesion in
which FAK is involved. However, such mechanism was
not affected in the SK-MES-1 cells of Psoriasin
Figure 5 Effect of Psoriasin knockdown and over-expression on invasion and migration of NSCLC cells. A, Invasion was enhanced in SK-
MES-1 PsoExp cells, p=0.017 compared to SK-MES-1 PEF control cells. B, A549 PsoRib showed a reduction of invasion, p=0.004 compared to A549
PEF control. C and D, There was no change of migration seen in cells of both Psoriasin over-expression and knockdown in comparison with the
respective controls.
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ator or a factor involved in the adhesion, rather
than a key factor or an initiating factor.
The SK-MES-1 cells did exhibit an increased invasion
without obvious change in the p-FAK. In our recent
study of Psoriasin in prostate cancer cells, matrix metal-
loproteinases (MMPs) have been indicated in the effect
on invasion of cancer cells by Psoriasin [12]. After the
loss of adhesion, MMPs may be consequently affected
by the up-regulated Psoriasin leading to enhanced inva-
siveness. Although FAK has been linked to enhanced cell
adhesion and migration [25,26], certainly its role in the
regulation of these cellular functions appears to be more
complicated as contrasting effects on the same functions
by FAK have also been demonstrated [27]. Collectively
these observations suggest that Psoriasin is inversely
associated with the adhesiveness of lung cancer cells inwhich the FAK pathway may be involved. Psoriasin plays
a positive role in regulation of growth and invasion of
NSCLC cells.
Perhaps the most important observation seen in the
present study is the association between the higher levels
of Psoriasin transcripts and poor prognosis. These data
clearly indicate that Psoriasin is a promoting factor in
the disease progression of NSCLC and can be utilised as
a potential prognostic indicator which needs to be fur-
ther investigated in a larger cohort. Selective expression
of Psoriasin has been shown in certain types of lung can-
cer, such as squamous cell carcinomas and large cell car-
cinomas, but its expression appears to be lower or
absent from adenocarcinomas and small cell carcinomas
[22]. Psoriasin has also been indicated in the brain me-
tastasis of lung squamous cell carcinoma [11], which
may account for worse prognosis. Together with the
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sin has diagnostic and therapeutic value in NSCLC,
particularly for lung squamous carcinoma.
Conclusions
Taken together, the expression of Psoriasin is increased in
lung squamous carcinoma compared with normal lung
tissues and lung adenocarcinoma. The elevated expression
is associated with poorer overall survival. Psoriasin is
involved in the regulation of growth and invasion of
NSCLC cells, and its expression is inversely associated
with cell adhesion. These results indicate a prognostic and
therapeutic potential of Psoriasin in lung cancer.
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